| ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED) (NCT00975507) | Merck Sharp & Dohme LLC | 1998-03-01 |
| Extended Administration of Polyethylene Glycol (PEG) Interferon Alfa-2b in Participants With Solid Tumors (C/I97-349/MK-4031-009) (NCT03554005) | Merck Sharp & Dohme LLC | 1997-12-29 |
| Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016) (NCT03537274) | Merck Sharp & Dohme LLC | 1997-08-05 |
| Historical Control Study of Refractory IFI or Patients Intolerant to Standard Antifungal Therapy in Patients With Invasive Fungal Infections (Study P02387) (NCT00230243) | Merck Sharp & Dohme LLC | 1997-03-01 |
| Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083) (NCT00749684) | Merck Sharp & Dohme LLC | 1996-12-01 |
| A Study to Evaluate Long-term Impact of VARIVAX Among Children and Adolescents (V210-036)(COMPLETED) (NCT01077804) | Merck Sharp & Dohme LLC | 1995-06-01 |
| MK0954 Versus Placebo for Treatment of Mild to Moderate Hypertension (NCT00888355) | Merck Sharp & Dohme LLC | 1992-05-01 |
| A Study to Investigate the Antihypertensive Efficacy of MK0954 (NCT00887250) | Merck Sharp & Dohme LLC | 1991-12-01 |
| A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED) (NCT00886600) | Merck Sharp & Dohme LLC | 1991-05-01 |
| A Study to Investigate the Efficacy and Safety of Different Doses of Losartan Potassium (MK0954-011) (NCT00882440) | Merck Sharp & Dohme LLC | 1990-12-01 |
| MARS - Monitored Atherosclerosis Regression Study (NCT00116870) | Merck Sharp & Dohme LLC | 1985-06-01 |
| Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs (NCT00002451) | Merck Sharp & Dohme LLC | |
| Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole (NCT00005920) | Merck Sharp & Dohme LLC | |
| A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis (NCT00005921) | Merck Sharp & Dohme LLC | |
| Single Patient Treatment of Posaconazole in Invasive Fungal Infections (Study P05113) (NCT00686621) | Merck Sharp & Dohme LLC | |
| The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease (NCT00006187) | Merck Sharp & Dohme LLC | |
| Safety and Effectiveness of Giving Indinavir and Nelfinavir to HIV-Infected Patients (NCT00002375) | Merck Sharp & Dohme LLC | |
| Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia (NCT00002386) | Merck Sharp & Dohme LLC | |
| A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and Lamivudine (NCT00002424) | Merck Sharp & Dohme LLC | |
| A Study of L-735,524 in HIV-Positive Children and Adolescents (NCT00002351) | Merck Sharp & Dohme LLC | |
| The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment (NCT00005118) | Merck Sharp & Dohme LLC | |
| Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir (NCT00002220) | Merck Sharp & Dohme LLC | |
| A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine (NCT00000628) | Merck Sharp & Dohme LLC | |
| A Study on the Safety and Effectiveness of L-756423 Plus Indinavir in HIV-Positive Patients Who Have Previously Taken Indinavir (NCT00002452) | Merck Sharp & Dohme LLC | |
| A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors (NCT00002235) | Merck Sharp & Dohme LLC | |
| A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC (NCT00002155) | Merck Sharp & Dohme LLC | |
| Post Marketing Surveillance Study of Cuprimine (NCT01374282) | Merck Sharp & Dohme LLC | |
| Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease Inhibitors (NCT00002361) | Merck Sharp & Dohme LLC | |
| The Safety and Effectiveness of MK-639 and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs (NCT00002443) | Merck Sharp & Dohme LLC | |
| A Comparison of Two Dose Levels of Indinavir Combined With Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients (NCT00002406) | Merck Sharp & Dohme LLC | |
| Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily (NCT00002241) | Merck Sharp & Dohme LLC | |
| Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042) (NCT00419367) | Merck Sharp & Dohme LLC | |
| The Safety and Effectiveness of Indinavir Sulfate Plus Efavirenz (NCT00002387) | Merck Sharp & Dohme LLC | |
| A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients (NCT00002354) | Merck Sharp & Dohme LLC | |
| A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC (NCT00002208) | Merck Sharp & Dohme LLC | |
| The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection (NCT00002179) | Merck Sharp & Dohme LLC | |
| Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030) (NCT02083484) | Merck Sharp & Dohme LLC | |
| Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023) (NCT00377065) | Merck Sharp & Dohme LLC | |
| A Study to Compare the Effectiveness of Two Anti-HIV Drug Combinations (NCT00002430) | Merck Sharp & Dohme LLC | |
| The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients (NCT00002376) | Merck Sharp & Dohme LLC | |